NO20055449L - Fremgangsmate for diagnostisering av behandling av kreft - Google Patents
Fremgangsmate for diagnostisering av behandling av kreftInfo
- Publication number
- NO20055449L NO20055449L NO20055449A NO20055449A NO20055449L NO 20055449 L NO20055449 L NO 20055449L NO 20055449 A NO20055449 A NO 20055449A NO 20055449 A NO20055449 A NO 20055449A NO 20055449 L NO20055449 L NO 20055449L
- Authority
- NO
- Norway
- Prior art keywords
- claudin
- cell
- cancer
- procedure
- diagnosing cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 6
- 102000002029 Claudin Human genes 0.000 abstract 5
- 108050009302 Claudin Proteins 0.000 abstract 5
- 102000004106 Claudin-3 Human genes 0.000 abstract 2
- 108090000599 Claudin-3 Proteins 0.000 abstract 2
- 102000004161 Claudin-4 Human genes 0.000 abstract 2
- 108090000601 Claudin-4 Proteins 0.000 abstract 2
- 102000018157 Claudin-9 Human genes 0.000 abstract 2
- 108050007295 Claudin-9 Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46690503P | 2003-04-30 | 2003-04-30 | |
| PCT/US2004/013436 WO2004098647A2 (en) | 2003-04-30 | 2004-04-30 | Claudins’ underexpression as markers of tumor metastasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20055449D0 NO20055449D0 (no) | 2005-11-17 |
| NO20055449L true NO20055449L (no) | 2006-01-26 |
Family
ID=33434995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20055449A NO20055449L (no) | 2003-04-30 | 2005-11-17 | Fremgangsmate for diagnostisering av behandling av kreft |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040253211A1 (enExample) |
| EP (1) | EP1620732A2 (enExample) |
| JP (1) | JP2006525351A (enExample) |
| CN (1) | CN100575955C (enExample) |
| CA (1) | CA2523870A1 (enExample) |
| MX (1) | MXPA05011644A (enExample) |
| NO (1) | NO20055449L (enExample) |
| WO (1) | WO2004098647A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000061739A1 (fr) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2672581A1 (en) * | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same |
| EP2138576A4 (en) * | 2007-03-16 | 2011-02-23 | Kyowa Hakko Kirin Co Ltd | ANTI-CLAUDIN-4 ANTIBODY |
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| KR101741898B1 (ko) | 2015-05-27 | 2017-06-01 | 울산대학교 산학협력단 | Claudin 7을 포함하는 방사선 반응성 위암 진단용 바이오마커 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744166A (en) * | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
| US5554388A (en) * | 1989-02-25 | 1996-09-10 | Danbiosyst Uk Limited | Systemic drug delivery compositions comprising a polycationi substance |
| GB9202464D0 (en) * | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
| GB9310412D0 (en) * | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
| GB9412394D0 (en) * | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
| GB9419979D0 (en) * | 1994-10-04 | 1994-11-16 | Medeva Holdings Bv | Vaccine compositions |
| GB9522351D0 (en) * | 1995-11-01 | 1996-01-03 | Medeva Holdings Bv | Vaccine compositions |
| GB9525083D0 (en) * | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
| WO1998000013A1 (en) * | 1996-06-28 | 1998-01-08 | The Regents Of The University Of California | Enhancement of cancer cell death |
| WO1999027905A1 (en) * | 1997-12-02 | 1999-06-10 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited | Compositions for nasal administration |
| GB9726916D0 (en) * | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
| US6248864B1 (en) * | 1997-12-31 | 2001-06-19 | Adherex Technologies, Inc. | Compounds and methods and modulating tissue permeability |
| US7279294B2 (en) * | 2000-04-03 | 2007-10-09 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, Nih | Tumor markers in ovarian cancer |
| CN1234727C (zh) * | 2000-06-01 | 2006-01-04 | 北京双鹭药业股份有限公司 | 人胸腺素α原基因突变体合成、表达及应用 |
| WO2003069307A2 (en) * | 2002-02-14 | 2003-08-21 | The Johns Hopkins University School Of Medicine | Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer |
-
2004
- 2004-04-30 MX MXPA05011644A patent/MXPA05011644A/es not_active Application Discontinuation
- 2004-04-30 JP JP2006514176A patent/JP2006525351A/ja active Pending
- 2004-04-30 US US10/836,421 patent/US20040253211A1/en not_active Abandoned
- 2004-04-30 WO PCT/US2004/013436 patent/WO2004098647A2/en not_active Ceased
- 2004-04-30 CN CN200480018784A patent/CN100575955C/zh not_active Expired - Fee Related
- 2004-04-30 CA CA002523870A patent/CA2523870A1/en not_active Abandoned
- 2004-04-30 EP EP04751031A patent/EP1620732A2/en not_active Withdrawn
-
2005
- 2005-11-17 NO NO20055449A patent/NO20055449L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1816745A (zh) | 2006-08-09 |
| MXPA05011644A (es) | 2005-12-15 |
| WO2004098647A2 (en) | 2004-11-18 |
| JP2006525351A (ja) | 2006-11-09 |
| CN100575955C (zh) | 2009-12-30 |
| US20040253211A1 (en) | 2004-12-16 |
| NO20055449D0 (no) | 2005-11-17 |
| EP1620732A2 (en) | 2006-02-01 |
| CA2523870A1 (en) | 2004-11-18 |
| WO2004098647A3 (en) | 2005-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bachstetter et al. | Fractalkine and CX3CR1 regulate hippocampal neurogenesis in adult and aged rats | |
| Gangadharan Komala et al. | Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes | |
| Eddy | Overview of the cellular and molecular basis of kidney fibrosis | |
| Zanchi et al. | Botulinum toxin type‐A for the treatment of inverse psoriasis | |
| ATE511655T1 (de) | Verfahren zur auswertung eines myelounterdrückungszustands | |
| NO20061239L (no) | Fremgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser | |
| Escuin-Ordinas et al. | COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors | |
| HUP0302332A2 (hu) | Génkimutatási eljárás ErbB-antagonistával végzett rákterápiára adott hatékony reakció valószínûségének növelésére | |
| AR043188A1 (es) | Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias | |
| RU2009138327A (ru) | Композиции и способы направленного устранения мутационного ускользания в направленной терапии рака | |
| AR032743A1 (es) | Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon | |
| BR0308928A (pt) | Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular | |
| MX2021009388A (es) | Tratamiento de ciliopatias. | |
| NO20045354L (no) | Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser | |
| MX2021002349A (es) | Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario. | |
| Saiphoklang et al. | The effect of NINTEDANIB in post‐COVID‐19 lung fibrosis: an observational study | |
| NO20055449L (no) | Fremgangsmate for diagnostisering av behandling av kreft | |
| Pitt et al. | A double‐blind randomized placebo‐controlled trial of oral indoramin to treat chronic anal fissure | |
| Ahamadi et al. | Oncolytic viral kinetics mechanistic modeling of talimogene laherparepvec (T‐VEC) a first‐in‐class oncolytic viral therapy in patients with advanced melanoma | |
| NO20051669L (no) | Fremgangsmater og reagenser for behandling av sykdommer og forstyrrelser assosiert med okte nivaer av proinflammatoriske cytokiner | |
| Kaleczyc et al. | The distribution and chemical coding of intramural neurons supplying the porcine stomach–the study on normal pigs and on animals suffering from swine dysentery | |
| WO2020257586A3 (en) | Method of treatment with viral-based gene therapy | |
| Defamie et al. | Metalloproteinase inhibitors regulate biliary progenitor cells through sDLK1 in organoid models of liver injury | |
| MX2025001172A (es) | Compuestos para el tratamiento de afecciones y enfermedades | |
| MX2022014586A (es) | Métodos y composiciones para tratar la fuga vascular. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |